ELOX Eloxx Pharmaceuticals, Inc.
Listings ·
The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028.
The company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern.
Eloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025.
The late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $6.4 million |
| Net income (loss) | -$6.0 million | -$3.1 million |
| Cash from operations | -$6.3 million | -$4.7 million |
| Cash and equivalents | $4.8 million | $111,000 |
Our latest story on this, dated Aug 14, 2025: "Eloxx Pharmaceuticals lacks funds for auditor review, expects $0.6 million cash". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 11, 2026: "Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting". The story links the filing or release it is based on. Read the story.
Eloxx Pharmaceuticals, Inc. trades under the ticker ELOX on NASDAQ.
Eloxx Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Eloxx Pharmaceuticals, Inc. is 1035354. Its filings are on SEC EDGAR.
4,036,459 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Eloxx Pharmaceuticals, Inc. under United States.
Our directory classifies Eloxx Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Eloxx Pharmaceuticals, Inc. is US29014R3012.
aibio.space lists Eloxx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Eloxx Pharmaceuticals, Inc. reported a net loss of $6.0 million for the fiscal year ended Dec 31, 2025, and used $6.3 million of cash in operations, per its annual report to the SEC.
$62.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Eloxx Pharmaceuticals, dated Aug 11, 2026: "Eloxx reports second-quarter results after a $66.0 million offering and Nasdaq uplisting". The company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028. Source.
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio